PMID-38018310 – GLP-1RA Thyroid Cancer Risk: Meta-Analysis of RCTs
Silverii GA et al. "Glucagon-like peptide-1 receptor agonists and the risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials," Diabetes, Obesity and Metabolism, 2024;26(3):891-897. doi:10.1111/dom.15382
Quick Reference
| Property | Value |
|---|---|
| PMID | 38018310 |
| DOI | 10.1111/dom.15382 |
| Year | 2024 |
| Journal | Diabetes, Obesity and Metabolism |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 64 RCTs pooled |
| Peptide(s) Studied | Semaglutide, Tirzepatide |
Key Findings
- Thyroid cancer odds ratio of 1.52 (95% CI 1.02-2.27) with GLP-1RA use vs. comparator
- This translates to approximately 1 additional thyroid cancer case per 1,349 patients treated over 5 years
- The signal was primarily driven by medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma
- Signal was more prominent with longer-duration use (>1 year)
- The absolute risk increase is very small but statistically significant
- Results are consistent with the known rodent C-cell activation signal but at a much lower magnitude than predicted from animal data
Study Design
Systematic review and meta-analysis of 64 randomized controlled trials reporting thyroid cancer as an adverse event. Comprehensive search across major databases. Pre-specified subgroup analyses by GLP-1RA agent, duration of exposure, and thyroid cancer histotype. PRISMA-compliant methodology.
Limitations
- Thyroid cancer was a secondary adverse event, not a primary outcome, in all included trials
- Small number of thyroid cancer events despite large overall sample
- Detection bias possible — GLP-1RA label includes thyroid monitoring recommendations, potentially increasing detection of incidental thyroid cancers
- Cannot distinguish between causation and enhanced surveillance
- 5-year horizon may be insufficient for thyroid carcinogenesis
Clinical Relevance
This is the most rigorous thyroid-specific cancer risk analysis for GLP-1RAs. The OR of 1.52 is statistically significant but the absolute risk is very low (~1 per 1,349 over 5 years). This supports maintaining the existing FDA black-box warning for MTC family history but does not warrant withholding GLP-1RAs from the general population. Practitioners should screen for personal/family history of MTC or MEN2 before prescribing semaglutide or tirzepatide. Baseline thyroid assessment and periodic monitoring are recommended.
Related
#research #systematic-review #evidence-level-I #cancer